| 106.62 1.01 (0.96%) | 09-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 130.14  |
1-year : | 137.68 |
| Resists | First : | 111.42 |
Second : | 117.87 |
| Pivot price | 111.01 |
|||
| Supports | First : | 100.98 |
Second : | 84.02 |
| MAs | MA(5) : | 108.07 |
MA(20) : | 110.84 |
| MA(100) : | 95.45 |
MA(250) : | 67.05 |
|
| MACD | MACD : | 0.9 |
Signal : | 2.2 |
| %K %D | K(14,3) : | 17.2 |
D(3) : | 25.4 |
| RSI | RSI(14): 47.5 |
|||
| 52-week | High : | 117.87 | Low : | 23.7 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DNTH ] has closed above bottom band by 15.4%. Bollinger Bands are 10.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 107.67 - 108.27 | 108.27 - 108.82 |
| Low: | 103.06 - 103.85 | 103.85 - 104.57 |
| Close: | 105.47 - 106.62 | 106.62 - 107.67 |
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Tue, 01 Sep 2026
Officer at Dianthus (NASDAQ: DNTH) lines up 2026 stock sale after option exercise - Stock Titan
Tue, 01 Sep 2026
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results - Stocktwits
Sat, 22 Aug 2026
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It? - Eastern Progress
Fri, 14 Aug 2026
Sirenia Capital reveals 1.70M-share DNTH stake in Dianthus Therapeutics (DNTH) - Stock Titan
Thu, 13 Aug 2026
Dianthus Therapeutics (DNTH) Climbed, What Is Behind The Move? - simplywall.st
Tue, 28 Jul 2026
DNTH News | DIANTHUS THERAPEUTICS INC (NASDAQ:DNTH) - ChartMill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 5.585e+007 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 9,530 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.1772e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 79.1 % |
| Return on Equity (ttm) | -17.7 % |
| Qtrly Rev. Growth | 1.9e+006 % |
| Gross Profit (p.s.) | 3678.75 |
| Sales Per Share | -325.88 |
| EBITDA (p.s.) | 2.375e+007 |
| Qtrly Earnings Growth | -4.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -155 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.33 |
| Price to Cash Flow | 0.39 |
| Dividend | 0 |
| Forward Dividend | 8.38e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|